Latest / Breastcancer.org Podcast

Verzenio Plus Faslodex Improves Survival in Metastatic Hormone-Receptor-Positive, HER2-Negative Breast Cancer, Regardless of Menopausal Status
Dr. George Sledge is professor of medicine and head of the Oncology Division at Stanford University. A former president of the American Society of Clinical Oncology, he specializes in breast cancer research. He has published extensively on the treatment of metastatic breast cancer and has been honored with numerous awards for his work.
At the European Society for Medical Oncology 2019 Congress, he presented overall survival results from the MONARCH 2 study, which used Verzenio (chemical name: abemaciclib) and Faslodex (chemical name: fulvestrant) to treat metastatic hormone-receptor-positive…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.